HIV-RNA decay in paired blood and semen samples of subjects receiving their first dolutegravir-based ART regimen

Claudia Fabrizio, Nicolò de Gennaro, Anna Volpe, Luigia Scudeller, Antonella Lagioia, Katia Falasca, Nicoletta Ladisa, Gioacchino Angarano, Laura Monno, Annalisa Saracino

Research output: Contribution to journalArticle

Abstract

Background and objectives: We aimed to investigate to what extent a first-line DTG-based ART regimen reduces HIV-RNA in semen compared to plasma. Study design: In this prospective, observational study, ART-naïve, HIV-infected males starting their first ART regimen with DTG plus TDF/FTC or ABC/3TC were enrolled. Paired blood (BP) and seminal plasma (SP) samples were collected at baseline (T0) and at week-2/4/12/24 after ART initiation. Sexually transmitted infections (STI) were ruled out before enrolment. Results: Median baseline HIV-RNA levels were lower in SP compared to BP (657 versus 38.200 copies/ml, p < 0.001), three subjects had undetectable semen HIV-RNA. After 12 weeks of treatment, HIV-RNA was below the quantification limit in both BP and SP of 11 pts (61.1%). Discordant results were obtained in 6 subjects (33.3%), showing quantifiable HIV-RNA in blood only (2 cases) and in semen only (4 cases). Finally, one subject had a positive HIV-RNA in SP/BP. At W24, only in 2/16 subjects (12.5%) HIV-RNA was detectable in semen, while in the others it was negative on SP/BP. No concurrent STI was found in subjects with detectable VL in semen. Conclusions: DTG demonstrated effectiveness in reducing VL with different kinetics in blood and semen, despite seminal viral suppression after 6 months of ART was not obtained in the totality of subjects.

Original languageEnglish
Pages (from-to)45-49
Number of pages5
JournalJournal of Clinical Virology
Volume109
DOIs
Publication statusPublished - Dec 1 2018

Fingerprint

RNA Stability
Semen
HIV
RNA
Sexually Transmitted Diseases
dolutegravir
Lamivudine
Observational Studies
Prospective Studies

Keywords

  • Antiretroviral therapy
  • Dolutegravir
  • HIV
  • Semen
  • Sexual transmission

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Cite this

HIV-RNA decay in paired blood and semen samples of subjects receiving their first dolutegravir-based ART regimen. / Fabrizio, Claudia; de Gennaro, Nicolò; Volpe, Anna; Scudeller, Luigia; Lagioia, Antonella; Falasca, Katia; Ladisa, Nicoletta; Angarano, Gioacchino; Monno, Laura; Saracino, Annalisa.

In: Journal of Clinical Virology, Vol. 109, 01.12.2018, p. 45-49.

Research output: Contribution to journalArticle

Fabrizio, Claudia ; de Gennaro, Nicolò ; Volpe, Anna ; Scudeller, Luigia ; Lagioia, Antonella ; Falasca, Katia ; Ladisa, Nicoletta ; Angarano, Gioacchino ; Monno, Laura ; Saracino, Annalisa. / HIV-RNA decay in paired blood and semen samples of subjects receiving their first dolutegravir-based ART regimen. In: Journal of Clinical Virology. 2018 ; Vol. 109. pp. 45-49.
@article{467fb00103dc4f60a0856035c5a947d1,
title = "HIV-RNA decay in paired blood and semen samples of subjects receiving their first dolutegravir-based ART regimen",
abstract = "Background and objectives: We aimed to investigate to what extent a first-line DTG-based ART regimen reduces HIV-RNA in semen compared to plasma. Study design: In this prospective, observational study, ART-na{\"i}ve, HIV-infected males starting their first ART regimen with DTG plus TDF/FTC or ABC/3TC were enrolled. Paired blood (BP) and seminal plasma (SP) samples were collected at baseline (T0) and at week-2/4/12/24 after ART initiation. Sexually transmitted infections (STI) were ruled out before enrolment. Results: Median baseline HIV-RNA levels were lower in SP compared to BP (657 versus 38.200 copies/ml, p < 0.001), three subjects had undetectable semen HIV-RNA. After 12 weeks of treatment, HIV-RNA was below the quantification limit in both BP and SP of 11 pts (61.1{\%}). Discordant results were obtained in 6 subjects (33.3{\%}), showing quantifiable HIV-RNA in blood only (2 cases) and in semen only (4 cases). Finally, one subject had a positive HIV-RNA in SP/BP. At W24, only in 2/16 subjects (12.5{\%}) HIV-RNA was detectable in semen, while in the others it was negative on SP/BP. No concurrent STI was found in subjects with detectable VL in semen. Conclusions: DTG demonstrated effectiveness in reducing VL with different kinetics in blood and semen, despite seminal viral suppression after 6 months of ART was not obtained in the totality of subjects.",
keywords = "Antiretroviral therapy, Dolutegravir, HIV, Semen, Sexual transmission",
author = "Claudia Fabrizio and {de Gennaro}, Nicol{\`o} and Anna Volpe and Luigia Scudeller and Antonella Lagioia and Katia Falasca and Nicoletta Ladisa and Gioacchino Angarano and Laura Monno and Annalisa Saracino",
year = "2018",
month = "12",
day = "1",
doi = "10.1016/j.jcv.2018.11.002",
language = "English",
volume = "109",
pages = "45--49",
journal = "Journal of Clinical Virology",
issn = "1386-6532",
publisher = "Elsevier",

}

TY - JOUR

T1 - HIV-RNA decay in paired blood and semen samples of subjects receiving their first dolutegravir-based ART regimen

AU - Fabrizio, Claudia

AU - de Gennaro, Nicolò

AU - Volpe, Anna

AU - Scudeller, Luigia

AU - Lagioia, Antonella

AU - Falasca, Katia

AU - Ladisa, Nicoletta

AU - Angarano, Gioacchino

AU - Monno, Laura

AU - Saracino, Annalisa

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Background and objectives: We aimed to investigate to what extent a first-line DTG-based ART regimen reduces HIV-RNA in semen compared to plasma. Study design: In this prospective, observational study, ART-naïve, HIV-infected males starting their first ART regimen with DTG plus TDF/FTC or ABC/3TC were enrolled. Paired blood (BP) and seminal plasma (SP) samples were collected at baseline (T0) and at week-2/4/12/24 after ART initiation. Sexually transmitted infections (STI) were ruled out before enrolment. Results: Median baseline HIV-RNA levels were lower in SP compared to BP (657 versus 38.200 copies/ml, p < 0.001), three subjects had undetectable semen HIV-RNA. After 12 weeks of treatment, HIV-RNA was below the quantification limit in both BP and SP of 11 pts (61.1%). Discordant results were obtained in 6 subjects (33.3%), showing quantifiable HIV-RNA in blood only (2 cases) and in semen only (4 cases). Finally, one subject had a positive HIV-RNA in SP/BP. At W24, only in 2/16 subjects (12.5%) HIV-RNA was detectable in semen, while in the others it was negative on SP/BP. No concurrent STI was found in subjects with detectable VL in semen. Conclusions: DTG demonstrated effectiveness in reducing VL with different kinetics in blood and semen, despite seminal viral suppression after 6 months of ART was not obtained in the totality of subjects.

AB - Background and objectives: We aimed to investigate to what extent a first-line DTG-based ART regimen reduces HIV-RNA in semen compared to plasma. Study design: In this prospective, observational study, ART-naïve, HIV-infected males starting their first ART regimen with DTG plus TDF/FTC or ABC/3TC were enrolled. Paired blood (BP) and seminal plasma (SP) samples were collected at baseline (T0) and at week-2/4/12/24 after ART initiation. Sexually transmitted infections (STI) were ruled out before enrolment. Results: Median baseline HIV-RNA levels were lower in SP compared to BP (657 versus 38.200 copies/ml, p < 0.001), three subjects had undetectable semen HIV-RNA. After 12 weeks of treatment, HIV-RNA was below the quantification limit in both BP and SP of 11 pts (61.1%). Discordant results were obtained in 6 subjects (33.3%), showing quantifiable HIV-RNA in blood only (2 cases) and in semen only (4 cases). Finally, one subject had a positive HIV-RNA in SP/BP. At W24, only in 2/16 subjects (12.5%) HIV-RNA was detectable in semen, while in the others it was negative on SP/BP. No concurrent STI was found in subjects with detectable VL in semen. Conclusions: DTG demonstrated effectiveness in reducing VL with different kinetics in blood and semen, despite seminal viral suppression after 6 months of ART was not obtained in the totality of subjects.

KW - Antiretroviral therapy

KW - Dolutegravir

KW - HIV

KW - Semen

KW - Sexual transmission

UR - http://www.scopus.com/inward/record.url?scp=85056820807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056820807&partnerID=8YFLogxK

U2 - 10.1016/j.jcv.2018.11.002

DO - 10.1016/j.jcv.2018.11.002

M3 - Article

VL - 109

SP - 45

EP - 49

JO - Journal of Clinical Virology

JF - Journal of Clinical Virology

SN - 1386-6532

ER -